Work

Metabolic–epigenetic coupling driven by the SIRT3–PDHA1 axis mediates osteoclast differentiation

Year: 2026
Type: article
Abstract: Postmenopausal osteoporosis (PMOP) is a prevalent metabolic bone disease marked by excessive osteoclast activation. Osteoclast differentiation requires coordinated metabolic and epigenetic reprogramming to sustain the energy-intensive process of bone resorption; however, how these two layers are functionally coupled remains unclear. Here, we identify the SIRT3–PDHA1 axis as a pivotal hub linking mitochondrial metabolism to nuclear epigenetic regulation during osteoclastogenesis. SIRT3 expression is markedly upregulated during osteoclast differentiation both in vitro and in vivo . Genetic ablation or pharmacological inhibition of SIRT3 profoundly impairs osteoclast formation and suppresses pyruvate dehydrogenase (PDH) activity. Mechanistically, SIRT3 deacetylates PDHA1 at lysine-83, thereby activating the PDH complex to enhance pyruvate-to-acetyl-CoA conversion, tricarboxylic acid (TCA) cycle flux, and oxidative phosphorylation. Notably, loss of SIRT3 diminishes PDHA1 nuclear translocation and nuclear acetyl-CoA availability, leading to reduced histone H3K9/H3K27 acetylation and repression of osteoclastogenic gene expression. Notably, targeted delivery of the SIRT3-specific inhibitor 3-TYP via an osteoclast-directed liposomal system effectively preserves bone mass in ovariectomized mice. Collectively, these findings establish the SIRT3–PDHA1 axis as a central mediator of metabolic–epigenetic coupling in osteoclast differentiation and highlight osteoclast-specific metabolic inhibition as a promising precision strategy for postmenopausal osteoporosis.
Language: English
Open Access status: gold
Estimated APC paid: $2,600
OpenAlex ID: W7204635781
FWCI:
Cites: 53
Cited by:
Related to: 10